These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 7542644)

  • 1. The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha.
    Cordero OJ; Sarandeses C; López-Rodríguez JL; Nogueira M
    Immunopharmacology; 1995 Apr; 29(3):215-23. PubMed ID: 7542644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 killer cells: in vitro evaluation of combination with prothymosin alpha.
    López-Rodríguez JL; Cordero OJ; Sarandeses C; Viñuela J; Nogueira M
    Lymphokine Cytokine Res; 1994 Jun; 13(3):175-82. PubMed ID: 7948426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential oncolytic effect of NK-enriched subsets in long-term interleukin-2 cultures.
    Fuchshuber PR; Lotzová E
    Lymphokine Cytokine Res; 1992 Oct; 11(5):271-6. PubMed ID: 1281676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
    Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
    Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
    Roussel E; Gerrard JM; Greenberg AH
    Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.
    Eckert K; Grünberg E; Immenschuh P; Garbin F; Kreuser ED; Maurer HR
    J Cancer Res Clin Oncol; 1997; 123(8):420-8. PubMed ID: 9292704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prothymosin alpha enhances human natural killer cell cytotoxicity: role in mediating signals for NK activity.
    Cordero OJ; Sarandeses CS; López JL; Nogueira M
    Lymphokine Cytokine Res; 1992 Oct; 11(5):277-85. PubMed ID: 1467368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
    Fuchshuber PR; Lotzová E; Pollock RE
    Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
    Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
    Subauste CS; Dawson L; Remington JS
    J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of lymphokine-activated killer activity in mice by prothymosin alpha.
    Baxevanis CN; Gritzapis AD; Dedoussis GV; Papadopoulos NG; Tsolas O; Papamichail M
    Cancer Immunol Immunother; 1994 Apr; 38(4):281-6. PubMed ID: 8168124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.
    Zupo S; Azzoni L; Massara R; D'Amato A; Perussia B; Ferrarini M
    J Clin Immunol; 1993 May; 13(3):228-36. PubMed ID: 7686565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
    Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
    Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to adhesion molecules inhibit the lytic function of MHC-unrestricted cytotoxic cells by preventing their activation.
    Zarcone D; Viale O; Cerruti G; Tenca C; Malorni W; Arancia G; Iosi F; Galandrini R; Velardi A; Moretta A
    Cell Immunol; 1992 Sep; 143(2):389-404. PubMed ID: 1380897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
    Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
    Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD16- CD56+ natural killer cells after bone marrow transplantation.
    Jacobs R; Stoll M; Stratmann G; Leo R; Link H; Schmidt RE
    Blood; 1992 Jun; 79(12):3239-44. PubMed ID: 1375847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12.
    Bennett IM; Zatsepina O; Zamai L; Azzoni L; Mikheeva T; Perussia B
    J Exp Med; 1996 Nov; 184(5):1845-56. PubMed ID: 8920872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of an early myelopoietic antigen (CD33) on a subset of human umbilical cord blood-derived natural killer cells.
    Handgretinger R; Schäfer HJ; Baur F; Frank D; Ottenlinger C; Bühring HJ; Niethammer D
    Immunol Lett; 1993 Aug; 37(2-3):223-8. PubMed ID: 7505004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.